Ranitidine (Zantac)
FDA Findings
On April 1, 2020, the U.S. Food and Drug Administration (FDA) requested that all ranitidine (Zantac) products be pulled from the market immediately. The FDA discovered that a probable human carcinogen, N-Nitrosodimethylamine (NDMA), increases within Zantac over time, especially if stored in higher than room temperature areas. In fact, the FDA found NDMA in Zantac at levels far above FDA-approved standards. NDMA has been linked to cancer, liver fibrosis and scarring, tumors in the liver, kidneys, and lungs.
What is Zantac?
Zantac is the trade name for Ranitidine and it is a popular medication that reduces the body’s production of stomach acid. The medication has been sold over the counter and by prescription for decades to treat and prevent ulcers of the stomach and intestines, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, peptic ulcer disease, acid indigestion, and heartburn. Currently, Ranitidine is the 50th most prescribed medication in the United States.
How Lightfoot Law, PLLC can help?
Senior Counsel, Je Yon Jung, was recently appointed to the leadership of the Zantac Multi-District Litigation before Judge Rosenberg in U.S. District Court in Florida. She will play a key role in the national litigation and discovery related to the hundreds of Zantac cases filed throughout the country. Lightfoot Law filed the first Zantac case in the District of Columbia. For more information about Zantac, go https://www.lightfootlawdc.com/practice-areas/mass-torts/zantac-claims/. Contact us for a free consultation at (202) 506.3591 or info@maylightfootlaw.com.